Effects of pentoxifylline on canine platelet aggregation

Abstract Background Pentoxifylline can decrease platelet function in humans, but the anti‐platelet effects of pentoxifylline in dogs is unknown. The addition of a luciferin–luciferase reagent during platelet aggregometry can induce a dose‐dependent potentiation of platelet aggregation. Objective To...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	John M. Thomason, Todd M. Archer, Robert W. Wills, Andrew J. Mackin
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	dog pentoxifylline platelet Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/795e171e29aa4d49bac22d819e2394bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:795e171e29aa4d49bac22d819e2394bb
record_format	dspace
spelling	oai:doaj.org-article:795e171e29aa4d49bac22d819e2394bb2021-11-19T17:14:25ZEffects of pentoxifylline on canine platelet aggregation2053-109510.1002/vms3.595https://doaj.org/article/795e171e29aa4d49bac22d819e2394bb2021-11-01T00:00:00Zhttps://doi.org/10.1002/vms3.595https://doaj.org/toc/2053-1095Abstract Background Pentoxifylline can decrease platelet function in humans, but the anti‐platelet effects of pentoxifylline in dogs is unknown. The addition of a luciferin–luciferase reagent during platelet aggregometry can induce a dose‐dependent potentiation of platelet aggregation. Objective To determine if exposure to pentoxifylline, without the addition of a luciferin–luciferase reagent during aggregometry, causes canine platelet dysfunction. Our hypotheses were that pentoxifylline would inhibit platelet function, and that the addition of a luciferin–luciferase reagent would obscure detection of pentoxifylline‐induced platelet dysfunction as measured via aggregometry. Methods Seven healthy Walker hound dogs. Platelet‐rich plasma (PRP) and whole blood were treated for 30 minutes with pentoxifylline: 0 (control), 1 and 2 μg/mL. The platelet aggregation was determined using optical (maximum amplitude) and impedance (ohms) aggregometry using collagen as the agonists, with and without a luciferin–luciferase reagent. Four samples were analysed per concentration and the results were averaged. Results Based on optical aggregometry, there was no difference (p = 0.964) in the mean maximum amplitude at any pentoxifylline concentration, with and without the luciferin–luciferase reagent. During impedance aggregometry, the addition of a luciferin–luciferase reagent was associated with significantly (p < 0.001) greater platelet aggregation in response to a collagen agonist, regardless of the presence or absence of pentoxifylline. Conclusions Pentoxifylline does not exert an in vitro anti‐platelet effect on canine platelet aggregation when collagen is used as an agonist, but it is unknown if long‐term oral drug administration will inhibit platelet aggregation. The addition of a luciferin–luciferase reagent during platelet aggregometry can artificially enhance canine platelet aggregation.John M. ThomasonTodd M. ArcherRobert W. WillsAndrew J. MackinWileyarticledogpentoxifyllineplateletVeterinary medicineSF600-1100ENVeterinary Medicine and Science, Vol 7, Iss 6, Pp 2178-2184 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dog pentoxifylline platelet Veterinary medicine SF600-1100
spellingShingle	dog pentoxifylline platelet Veterinary medicine SF600-1100 John M. Thomason Todd M. Archer Robert W. Wills Andrew J. Mackin Effects of pentoxifylline on canine platelet aggregation
description	Abstract Background Pentoxifylline can decrease platelet function in humans, but the anti‐platelet effects of pentoxifylline in dogs is unknown. The addition of a luciferin–luciferase reagent during platelet aggregometry can induce a dose‐dependent potentiation of platelet aggregation. Objective To determine if exposure to pentoxifylline, without the addition of a luciferin–luciferase reagent during aggregometry, causes canine platelet dysfunction. Our hypotheses were that pentoxifylline would inhibit platelet function, and that the addition of a luciferin–luciferase reagent would obscure detection of pentoxifylline‐induced platelet dysfunction as measured via aggregometry. Methods Seven healthy Walker hound dogs. Platelet‐rich plasma (PRP) and whole blood were treated for 30 minutes with pentoxifylline: 0 (control), 1 and 2 μg/mL. The platelet aggregation was determined using optical (maximum amplitude) and impedance (ohms) aggregometry using collagen as the agonists, with and without a luciferin–luciferase reagent. Four samples were analysed per concentration and the results were averaged. Results Based on optical aggregometry, there was no difference (p = 0.964) in the mean maximum amplitude at any pentoxifylline concentration, with and without the luciferin–luciferase reagent. During impedance aggregometry, the addition of a luciferin–luciferase reagent was associated with significantly (p < 0.001) greater platelet aggregation in response to a collagen agonist, regardless of the presence or absence of pentoxifylline. Conclusions Pentoxifylline does not exert an in vitro anti‐platelet effect on canine platelet aggregation when collagen is used as an agonist, but it is unknown if long‐term oral drug administration will inhibit platelet aggregation. The addition of a luciferin–luciferase reagent during platelet aggregometry can artificially enhance canine platelet aggregation.
format	article
author	John M. Thomason Todd M. Archer Robert W. Wills Andrew J. Mackin
author_facet	John M. Thomason Todd M. Archer Robert W. Wills Andrew J. Mackin
author_sort	John M. Thomason
title	Effects of pentoxifylline on canine platelet aggregation
title_short	Effects of pentoxifylline on canine platelet aggregation
title_full	Effects of pentoxifylline on canine platelet aggregation
title_fullStr	Effects of pentoxifylline on canine platelet aggregation
title_full_unstemmed	Effects of pentoxifylline on canine platelet aggregation
title_sort	effects of pentoxifylline on canine platelet aggregation
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/795e171e29aa4d49bac22d819e2394bb
work_keys_str_mv	AT johnmthomason effectsofpentoxifyllineoncanineplateletaggregation AT toddmarcher effectsofpentoxifyllineoncanineplateletaggregation AT robertwwills effectsofpentoxifyllineoncanineplateletaggregation AT andrewjmackin effectsofpentoxifyllineoncanineplateletaggregation
_version_	1718420020401274880

Effects of pentoxifylline on canine platelet aggregation

Ejemplares similares